Approval of Bristol Myers Squibb and Bluebird bio's Abecma expands use of CAR-T treatment beyond leukemia and lymphoma.
Original source: https://www.healthcaredive.com/news/fda-car-t-multiple-myeloma-approval-bristol-myers-bluebird/597472/
Approval of Bristol Myers Squibb and Bluebird bio's Abecma expands use of CAR-T treatment beyond leukemia and lymphoma.
Original source: https://www.healthcaredive.com/news/fda-car-t-multiple-myeloma-approval-bristol-myers-bluebird/597472/